Table 2.

Conditions to consider when determining therapeutic options

Change	Risk
Decreased cardiac function	Use of endoscopic therapy
	Use of beta-blockers
	Increase in blood pressure caused by molecular targeted agent
Decreased renal function	Use of contrast medium
	Use of interventional radiology for hepatocellular carcinoma
	Rapid change in circulation dynamics
Decreased respiratory function	Aspiration pneumonia
Ease of electrolyte abnormalities	Higher risk of using diuretics
Dementia	Difficulty in differentiating hepatic encephalopathy from dementia and cerebrovascular diseases
Aging of gut microbiota	Hepatic encephalopathy
Loss of bone density	Osteoporosis
	Risk of fall-related injury
Loss of muscle volume	Sarcopenia
	Risk of fall-related injury
Dry skin	Pruritus
	Hand–foot syndrome caused by molecular targeted agent